Trial Profile

A clinical study to evaluate of Triferic iron delivery via dialysate in Chinese hemodialysis (HD) patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ferric pyrophosphate (Primary)
Indications Iron deficiency anaemia
Focus Adverse reactions; Pharmacokinetics; Registrational

Most Recent Events

21 Aug 2019 New trial record
08 Aug 2019 According to a Rockwell Medical media release, Rockwell Medical and its partner, Wanbang Biopharmaceuticals (Wanbang) expect to request a meeting with the National Medical Products Administration(NMPA) (formerly, China Food and Drug Administration or CFDA) to review the results of two clinical studies in Chinese population and discuss whether these studies are sufficient to support a submission for regulatory approval for Dialysate Triferic.
08 Aug 2019 Results presented in a Rockwell Medical media release media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com